We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+6.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$216M
AUM Growth
-$2.51M
(-1.1%)
Cap. Flow
-$7.44M
Cap. Flow
% of AUM
-3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMED
Amedisys
AMED
|
+$3.63M |
| 2 |
Capri Holdings
CPRI
|
+$3.52M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$3.22M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$3.13M |
| 5 |
Structure Therapeutics
GPCR
|
+$2.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$5.49M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
+$3.86M |
| 3 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$3.59M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.49M |
| 5 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.09% |
| 2 | Technology | 13.85% |
| 3 | Consumer Discretionary | 6.89% |
| 4 | Financials | 3.51% |
| 5 | Communication Services | 3.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
| $35.8M | 16.59% |
1,436,136
| – | – |
|
|
ATVI
2
DELISTED
Activision Blizzard
ATVI
| $5.76M | 2.67% |
61,520
| – | – |
|
|
VMW
3
DELISTED
VMware, Inc
VMW
| $5.59M | 2.59% |
33,556
| – | – |
|
4
Albertsons Companies
ACI
$5.63B
| $4.29M | 1.99% |
188,753
| – | – |
|
5
Immunovant
IMVT
$8.11B
| $4.1M | 1.9% |
106,908
-73,412
| -41% | -$1.66M |
|
|
6
Capri Holdings
CPRI
$1.82B
| $4.09M | 1.89% |
+77,700
| New | +$3.52M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.04M | 1.87% |
34,954
| – | – |
|
|
SPLK
8
DELISTED
Splunk Inc
SPLK
| $4.04M | 1.87% |
+27,600
| New | +$3.13M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.03M | 1.87% |
19,015
| – | – |
|
10
Axsome Therapeutics
AXSM
$12.1B
| $3.98M | 1.84% |
56,964
+7,564
| +15% | +$565K |
|
|
11
Structure Therapeutics
GPCR
$3.52B
| $3.77M | 1.75% |
+74,832
| New | +$2.41M |
|
|
AMED
12
DELISTED
Amedisys
AMED
| $3.67M | 1.7% |
+39,250
| New | +$3.63M |
|
|
13
IDEAYA Biosciences
IDYA
$3.5B
| $3.42M | 1.58% |
+126,845
| New | +$3.22M |
|
|
14
MoonLake Immunotherapeutics
MLTX
$1.62B
| $3.41M | 1.58% |
59,769
-69,953
| -54% | -$3.86M |
|
15
Microsoft
MSFT
$3.35T
| $3.14M | 1.46% |
9,958
-1,400
| -12% | -$463K |
|
|
TXNM
16
TXNM Energy Inc
TXNM
$6.42B
| $3.12M | 1.44% |
69,909
| – | – |
|
17
Olema Pharmaceuticals
OLMA
$1.03B
| $3.06M | 1.42% |
247,880
-44,396
| -15% | -$453K |
|
18
Legend Biotech
LEGN
$3.69B
| $2.98M | 1.38% |
44,305
+7,920
| +22% | +$550K |
|
|
MRUS
19
DELISTED
Merus
MRUS
| $2.89M | 1.34% |
122,631
+88,604
| +260% | +$2.15M |
|
20
Indivior Pharmaceuticals
INDV
$4.75B
| $2.82M | 1.31% |
130,000
| – | – |
|
|
ACLX
21
DELISTED
Arcellx
ACLX
| $2.8M | 1.3% |
78,028
+15,159
| +24% | +$523K |
|
|
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
| $2.69M | 1.24% |
180,305
-158,537
| -47% | -$2.1M |
|
|
NUVL
23
DELISTED
Nuvalent
NUVL
| $2.49M | 1.15% |
54,083
-18,215
| -25% | -$808K |
|
|
IMGN
24
DELISTED
Immunogen Inc
IMGN
| $2.3M | 1.06% |
+144,772
| New | +$2.41M |
|
|
AMAM
25
DELISTED
Ambrx Biopharma Inc
AMAM
| $2.23M | 1.03% |
193,701
+40,270
| +26% | +$548K |
|
Similar funds
SIAG
MS
WI
BHBT
WTFG
RC
VIA
A6
HighVista Strategies's Q3 2023 Portfolio in Review
As of Q3 2023, HighVista Strategies held 172 positions worth $216M, down 1.1% from $219M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
HighVista Strategies withdrew a net $7.44M in Q3 2023, closing 40 positions and reducing 47 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $5.49M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, HighVista Strategies opened a new position in Amedisys worth $3.67M.
- HighVista Strategies's largest Q3 2023 buy was Amedisys: 39,250 shares worth $3.67M.
- HighVista Strategies added most to Merus in Q3 2023, an estimated $2.15M increase.
- HighVista Strategies's biggest Q3 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $3.86M.
- HighVista Strategies fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.49M.
- HighVista Strategies's ten largest holdings make up 35% of its $216M portfolio in Q3 2023.
- HighVista Strategies opened 38 new positions and closed 40 in Q3 2023.
- HighVista Strategies's portfolio value fell 1.1% quarter-over-quarter to $216M.
Based on HighVista Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.